These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 9385477)

  • 41. Interferon beta-1b for the treatment of multiple sclerosis.
    Petri T; Weber-Diehl F
    J Biotechnol; 1995 Nov; 43(1):74-5. PubMed ID: 8573325
    [No Abstract]   [Full Text] [Related]  

  • 42. Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study.
    Hoffmann FA; Trenova A; Llaneza MA; Fischer J; Lus G; von Bredow D; Lara N; Lam E; Van Hoef M; Bakshi R
    BMC Neurol; 2017 Aug; 17(1):156. PubMed ID: 28793876
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interferon treatment for multiple sclerosis: autoimmune complications may be lethal.
    Durelli L; Bongioanni MR; Ferrero B; Oggero A; Marzano A; Rizzetto M
    Neurology; 1998 Feb; 50(2):570-1. PubMed ID: 9484407
    [No Abstract]   [Full Text] [Related]  

  • 44. Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS.
    Kracke A; von Wussow P; Al-Masri AN; Dalley G; Windhagen A; Heidenreich F
    Neurology; 2000 Jan; 54(1):193-9. PubMed ID: 10636147
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data.
    Bell C; Graham J; Earnshaw S; Oleen-Burkey M; Castelli-Haley J; Johnson K
    J Manag Care Pharm; 2007 Apr; 13(3):245-61. PubMed ID: 17407391
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lethal capillary leak syndrome after a single administration of interferon beta-1b.
    Schmidt S; Hertfelder HJ; von Spiegel T; Hering R; Harzheim M; Lassmann H; Deckert-Schlüter M; Schlegel U
    Neurology; 1999 Jul; 53(1):220-2. PubMed ID: 10408566
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Rudick RA; Goodkin DE; Jacobs LD; Cookfair DL; Herndon RM; Richert JR; Salazar AM; Fischer JS; Granger CV; Simon JH; Alam JJ; Simonian NA; Campion MK; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Whitham RH
    Neurology; 1997 Aug; 49(2):358-63. PubMed ID: 9270562
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical efficacy, effects on MRI and tolerability of weekly intramuscular interferon-beta-1a in patients with MS and CIS.
    Zivadinov R; Munschauer FE; Ramanathan M; Benedict RH; Weinstock-Guttman B
    Drugs Today (Barc); 2008 Aug; 44(8):601-13. PubMed ID: 18846271
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a.
    Zivadinov R; Zorzon M; Tommasi MA; Nasuelli D; Bernardi M; Monti-Bragadin L; Cazzato G
    J Neurol Sci; 2003 Dec; 216(1):113-8. PubMed ID: 14607312
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Quality of life during the first 6 months of interferon-beta treatment in patients with MS.
    Arnoldus JH; Killestein J; Pfennings LE; Jelles B; Uitdehaag BM; Polman CH
    Mult Scler; 2000 Oct; 6(5):338-42. PubMed ID: 11064444
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interferon beta-1b inhibits reactive oxygen species production in peripheral blood monocytes of patients with relapsing-remitting multiple sclerosis.
    Lucas M; Sánchez-Soliño O; Solano F; Izquierdo G
    Neurochem Int; 1998 Aug; 33(2):101-2. PubMed ID: 9761453
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interferon-beta treatment for patients with multiple sclerosis: the patients' perceptions of the side-effects.
    Gottberg K; Gardulf A; Fredrikson S
    Mult Scler; 2000 Oct; 6(5):349-54. PubMed ID: 11064446
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a.
    Mohr DC; Likosky W; Boudewyn AC; Marietta P; Dwyer P; Van der Wende J; Goodkin DE
    Mult Scler; 1998 Dec; 4(6):487-9. PubMed ID: 9987757
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
    Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
    BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical effects and tolerability of high-dose, high-frequency recombinant interferon beta-1a in patients with multiple sclerosis: maximizing therapy through long-term adherence.
    Boyko AN
    Expert Opin Biol Ther; 2010 Apr; 10(4):653-66. PubMed ID: 20218924
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term interferon beta-1b therapy for MS: is routine thyroid assessment always useful?
    Monzani F; Caraccio N; Casolaro A; Lombardo F; Moscato G; Murri L; Ferrannini E; Meucci G
    Neurology; 2000 Aug; 55(4):549-52. PubMed ID: 10953190
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG).
    Rudick RA; Simonian NA; Alam JA; Campion M; Scaramucci JO; Jones W; Coats ME; Goodkin DE; Weinstock-Guttman B; Herndon RM; Mass MK; Richert JR; Salazar AM; Munschauer FE; Cookfair DL; Simon JH; Jacobs LD
    Neurology; 1998 May; 50(5):1266-72. PubMed ID: 9595973
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.
    Río J; Tintoré M; Nos C; Téllez N; Galán I; Montalban X
    J Neurol; 2005 Jul; 252(7):795-800. PubMed ID: 15772741
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis.
    Webster GF; Knobler RL; Lublin FD; Kramer EM; Hochman LR
    J Am Acad Dermatol; 1996 Feb; 34(2 Pt 2):365-7. PubMed ID: 8655728
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interferon beta-1B--hope or hype?
    Drug Ther Bull; 1996 Feb; 34(2):9-11. PubMed ID: 8819985
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.